Logo-bi
Bioimpacts. 2018;8(2): 117-127. doi: 10.15171/bi.2018.14
PMID: 29977833        PMCID: PMC6026525

Original Research

Mucin-1 aptamer-armed superparamagnetic iron oxide nanoparticles for targeted delivery of doxorubicin to breast cancer cells

Ayuob Aghanejad 1, Hiwa Babamiri 1,2, Khosro Adibkia 1,2, Jaleh Barar 1,2 ORCID, Yadollah Omidi 1,2 * ORCID

Cited by CrossRef: 52

1- Fu Z, Xiang J. Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy. IJMS. 2020;21(23):9123 [Crossref]
2- Tyagi N, Gupta P, Khan Z, Neupane Y, Mangla B, Mehra N, Ralli T, Alhalmi A, Ali A, Al Kamaly O, Saleh A, Nasr F, Kohli K. Superparamagnetic Iron-Oxide Nanoparticles Synthesized via Green Chemistry for the Potential Treatment of Breast Cancer. Molecules. 2023;28(5):2343 [Crossref]
3- Hashemzadeh N, Dolatkhah M, Aghanejad A, Barzegar-Jalali M, Omidi Y, Adibkia K, Barar J. Folate Receptor-Mediated Delivery of 1-MDT-Loaded Mesoporous Silica Magnetic Nanoparticles to Target Breast Cancer Cells. Nanomedicine (Lond). 2021;16(24):2137 [Crossref]
4- Buvana S, Charles J, Subashini R. Biogenic Synthesis and Characterization of Biocompatible Iron Oxide Nanoparticles:In VitroStudy of Selective Antiproliferative Efficacy Against MCF-7 Cells and Antibacterial Potential. NANO. 2023;18(12) [Crossref]
5- Alphandéry E. Iron oxide nanoparticles for therapeutic applications. Drug Discovery Today. 2020;25(1):141 [Crossref]
6- Lin Y, Zhang K, Zhang R, She Z, Tan R, Fan Y, Li X. Magnetic nanoparticles applied in targeted therapy and magnetic resonance imaging: crucial preparation parameters, indispensable pre-treatments, updated research advancements and future perspectives. J Mater Chem B. 2020;8(28):5973 [Crossref]
7- Mulens-Arias V, Rojas J, Barber D. The Intrinsic Biological Identities of Iron Oxide Nanoparticles and Their Coatings: Unexplored Territory for Combinatorial Therapies. Nanomaterials. 2020;10(5):837 [Crossref]
8- Kadkhoda J, Akrami-Hasan-Kohal M, Tohidkia M, Khaledi S, Davaran S, Aghanejad A. Advances in antibody nanoconjugates for diagnosis and therapy: A review of recent studies and trends. International Journal of Biological Macromolecules. 2021;185:664 [Crossref]
9- Storjohann R, Gericke B, Reifenrath J, Herrmann T, Behrens P, Oltmanns H, Meißner J. Influence of PEG Chain Length of Functionalized Magnetic Nanoparticles on the Cytocompatibility and Immune Competence of Primary Murine Macrophages and Dendritic Cells. IJMS. 2023;24(3):2565 [Crossref]
10- Omidi Y, Mobasher M, Castejon A, Mahmoudi M. Recent advances in nanoscale targeted therapy of HER2-positive breast cancer. Journal of Drug Targeting. 2022;30(7):687 [Crossref]
11- Rahmanipour M, Siampour H, Moshaii A, Amirabadizadeh M, Fouani M, Shariati L, Rafienia M. Precision in cancer diagnostics: ultra-sensitive detection of MCF-7 breast cancer cells by gold nanostructure-enhanced electrochemical biosensing. J Mater Chem B. 2024;12(22):5551 [Crossref]
12- Dolatkhah M, Hashemzadeh N, Barar J, Adibkia K, Aghanejad A, Barzegar-Jalali M, Omidian H, Omidi Y. Stimuli-Responsive Graphene Oxide and Methotrexate-Loaded Magnetic Nanoparticles for Breast Cancer-Targeted Therapy. Nanomedicine (Lond). 2021;16(24):2155 [Crossref]
13- Foroughi-Nia B, Barar J, Memar M, Aghanejad A, Davaran S. Progresses in polymeric nanoparticles for delivery of tyrosine kinase inhibitors. Life Sciences. 2021;278:119642 [Crossref]
14- Fathi M, Barar J, Erfan-Niya H, Omidi Y. Methotrexate-conjugated chitosan-grafted pH- and thermo-responsive magnetic nanoparticles for targeted therapy of ovarian cancer. International Journal of Biological Macromolecules. 2020;154:1175 [Crossref]
15- Sanjanwala D, Patravale V. Aptamers and nanobodies as alternatives to antibodies for ligand-targeted drug delivery in cancer. Drug Discovery Today. 2023;28(5):103550 [Crossref]
16- Amiryaghoubi N, Fathi M, Barar J, Omidian H, Omidi Y. Advanced nanoscale drug delivery systems for bone cancer therapy. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2023;1869(6):166739 [Crossref]
17- Olenin A, Lisichkin G. Surface-Modified Oxide Nanoparticles: Synthesis and Application. Russ J Gen Chem. 2019;89(7):1451 [Crossref]
18- Tarighatnia A, Abdkarimi M, Nader N, Mehdipour T, Fouladi M, Aghanejad A, Ghadiri H. Mucin-16 targeted mesoporous nano-system for evaluation of cervical cancer via dual-modal computed tomography and ultrasonography. New J Chem. 2021;45(40):18871 [Crossref]
19- Shishparenok A, Furman V, Zhdanov D. DNA-Based Nanomaterials as Drug Delivery Platforms for Increasing the Effect of Drugs in Tumors. Cancers. 2023;15(7):2151 [Crossref]
20- Tarighatnia A, Fouladi M, Tohidkia M, Johal G, Nader N, Aghanejad A, Ghadiri H. Engineering and quantification of bismuth nanoparticles as targeted contrast agent for computed tomography imaging in cellular and animal models. Journal of Drug Delivery Science and Technology. 2021;66:102895 [Crossref]
21- Torabi M, Aghanejad A, Savadi P, Barzegari A, Omidi Y, Barar J. Targeted Delivery of Sunitinib by MUC-1 Aptamer-Capped Magnetic Mesoporous Silica Nanoparticles. Molecules. 2023;28(1):411 [Crossref]
22- Siminzar P, Omidi Y, Golchin A, Aghanejad A, Barar J. Targeted delivery of doxorubicin by magnetic mesoporous silica nanoparticles armed with mucin-1 aptamer. Journal of Drug Targeting. 2020;28(1):92 [Crossref]
23- Zhu M, Wang S. Functional Nucleic‐Acid‐Decorated Spherical Nanoparticles: Preparation Strategies and Current Applications in Cancer Therapy. Small Science. 2021;1(3) [Crossref]
24- Halder J, Pradhan D, Biswasroy P, Rai V, Kar B, Ghosh G, Rath G. Trends in iron oxide nanoparticles: a nano-platform for theranostic application in breast cancer. Journal of Drug Targeting. 2022;:1 [Crossref]
25- Si P, Shi J, Zhang P, Wang C, Chen H, Mi X, Chu W, Zhai B, Li W. MUC-1 recognition-based activated drug nanoplatform improves doxorubicin chemotherapy in breast cancer. Cancer Letters. 2020;472:165 [Crossref]
26- Shestovskaya M, Luss A, Bezborodova O, Makarov V, Keskinov A. Iron Oxide Nanoparticles in Cancer Treatment: Cell Responses and the Potency to Improve Radiosensitivity. Pharmaceutics. 2023;15(10):2406 [Crossref]
27- Gorbet M, Ranjan A. Cancer immunotherapy with immunoadjuvants, nanoparticles, and checkpoint inhibitors: Recent progress and challenges in treatment and tracking response to immunotherapy. Pharmacology & Therapeutics. 2020;207:107456 [Crossref]
28- Guan B, Zhang X.

Aptamers as Versatile Ligands for Biomedical and Pharmaceutical Applications

. IJN. 2020;Volume 15:1059 [Crossref]
29- Asgeirsson D, Christiansen M, Valentin T, Somm L, Mirkhani N, Nami A, Hosseini V, Schuerle S. 3D magnetically controlled spatiotemporal probing and actuation of collagen networks from a single cell perspective. Lab Chip. 2021;21(20):3850 [Crossref]
30- Kaur S, Singh D. A Short Appraisal of Magnetic Nanoparticles for Breast Cancer: In vitro and In vivo Research. NANOTEC. 2024;18(2):130 [Crossref]
31- Nabi P, Vahidfar N, Tohidkia M, Hamidi A, Omidi Y, Aghanejad A. Mucin-1 conjugated polyamidoamine-based nanoparticles for image-guided delivery of gefitinib to breast cancer. International Journal of Biological Macromolecules. 2021;174:185 [Crossref]
32- Dolatkhah M, Hashemzadeh N, Barar J, Adibkia K, Aghanejad A, Barzegar-Jalali M, Omidi Y. Graphene-based multifunctional nanosystems for simultaneous detection and treatment of breast cancer. Colloids and Surfaces B: Biointerfaces. 2020;193:111104 [Crossref]
33- Pandey S, Parul M, Santhanam M. Aptamer-guided Selective Delivery of Therapeutics to Breast Cancer Cells Expressing Specific Biomarkers. CCTR. 2024;20(5):434 [Crossref]
34- Safari B, Aghanejad A, Roshangar L, Davaran S. Osteogenic effects of the bioactive small molecules and minerals in the scaffold-based bone tissue engineering. Colloids and Surfaces B: Biointerfaces. 2021;198:111462 [Crossref]
35- Hashemzadeh N, Aghanejad A, Dalir Abdolahinia E, Dolatkhah M, Barzegar-Jalali M, Omidi Y, Barar J, Adibkia K. Targeted combined therapy in 2D and 3D cultured MCF-7 cells using metformin and erlotinib-loaded mesoporous silica magnetic nanoparticles. Journal of Microencapsulation. 2021;38(7-8):472 [Crossref]
36- Otieno E, Huang Y, Li N, Li T, Wang M, Qiu X, Xiao X. Utilization of superparamagnetic iron oxide nanoparticles (SPIONs) as a vector for drug delivery. Appl Nanosci. 2023;13(9):6191 [Crossref]
37- Janßen H, Angrisani N, Kalies S, Hansmann F, Kietzmann M, Warwas D, Behrens P, Reifenrath J. Biodistribution, biocompatibility and targeted accumulation of magnetic nanoporous silica nanoparticles as drug carrier in orthopedics. J Nanobiotechnol. 2020;18(1) [Crossref]
38- Aram E, Moeni M, Abedizadeh R, Sabour D, Sadeghi-Abandansari H, Gardy J, Hassanpour A. Smart and Multi-Functional Magnetic Nanoparticles for Cancer Treatment Applications: Clinical Challenges and Future Prospects. Nanomaterials. 2022;12(20):3567 [Crossref]
39- Kashyap A, Kumari M, Singh A, Mukherjee K, Maity D. Current development of theragnostic nanoparticles for women’s cancer treatment. Biomed Mater. 2024;19(4):042001 [Crossref]
40- Shetab Boushehri M, Dietrich D, Lamprecht A. Nanotechnology as a Platform for the Development of Injectable Parenteral Formulations: A Comprehensive Review of the Know-Hows and State of the Art. Pharmaceutics. 2020;12(6):510 [Crossref]
41- Al-Shalabi R, Abu-Huwaij R, Hamed R, Abbas M. The antimicrobial and the antiproliferative effect of human triple negative breast cancer cells using the greenly synthesized iron oxide nanoparticles. Journal of Drug Delivery Science and Technology. 2022;75:103642 [Crossref]

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate: 24% 
Publication fee: Free of charge